Sexually transmitted disease surveillance 2001 supplement; Gonococcal Isolate Surveillance Project (GISP) annual report, 2001
Published Date:October 2002
Corporate Authors:National Center for HIV, STD, and TB Prevention (U.S.), Division of STD Prevention.
Microbial Sensitivity Tests
Sexually Transmitted Diseases
Microbial Sensitivity Tests/Statistics
Neisseria Gonorrhoeae/Statistics/United States
Neisseria Gonorrhoeae/Susceptibility/Statistics/United States
Sexually Transmitted Diseases/Statistics/United States
Description:Introduction and overview -- Demographic and clinical data -- Susceptibility data -- Non-GISP susceptibility reporting -- Additional resources -- References -- Project figures -- Clinic-specific figures.
"With 361,705 gonorrhea cases reported in 2001, gonorrhea is the second most frequently reported communicable disease in the United States. Gonorrhea rates in the United States declined 73.8% during 1975-1997. However, in 1998, the reported rate of gonococcal infections in the United States (131.9 cases per 100,000 persons) increased by 7.8% compared with the 1997 rate (122.4 cases per 100,000 persons). In 2001, the gonorrhea rate was 128.5 cases per 100,000 population which represented little change from 1998. Gonorrhea rates remain high in the southeastern states, among minorities, and among adolescents of all racial and ethnic groups. The health impact of gonorrhea is largely related to its role as a major cause of pelvic inflammatory disease, which frequently leads to infertility or ectopic pregnancy. In addition, data suggest that gonorrhea facilitates HIV transmission. The treatment and control of gonorrhea has been complicated by the ability of Neisseria gonorrhoeae to develop resistance to antimicrobial agents. The appearance of penicillinase-producing N. gonorrhoeae (PPNG) and chromosomally mediated penicillin- and tetracycline-resistant N. gonorrhoeae (CMRNG) in the 1970s eventually led to the abandonment of these drugs as therapies for gonorrhea. The current CDC recommended primary therapies for gonorrhea are two broad-spectrum cephalosporins (ceftriaxone and cefixime), and three fluoroquinolones (ciprofloxacin, ofloxacin, and levofloxacin). However, since the 1990s, fluoroquinolone-resistant N. gonorrhoeae (QRNG) have been reported from many parts of the world, including the United States. The increased prevalence of QRNG in Asia (where prevalence in several countries exceeds 40%), the Pacific Islands, Hawaii, and, most recently, California, prompted CDC to recommend that fluroquinolones not be used to treat patients with gonorrhea acquired in these areas with high QRNG prevalence." -- p. 1.
Supporting Files:No Additional Files
You May Also Like: